Prenosis Secures $40M, Fuels AI Revolution in Critical Care
February 3, 2026, 9:34 pm
Prenosis secured $40M to transform critical care. A $20M Series A funds commercialization of Sepsis ImmunoScore, the FDA-authorized AI sepsis diagnostic. A $20M BARDA contract backs a pivotal trial for an AI companion diagnostic for corticosteroid use in severe respiratory infections. This moves critical care toward precision medicine. The company is building a national clinical trial network across top academic centers. This aims to personalize treatment, combating sepsis and other critical conditions with advanced AI solutions.
Chicago-based Prenosis announced a major financial milestone. The company secured $40 million in new capital. This funding splits evenly. A $20 million Series A round provides private investment. Premier co-investors include PACE Healthcare Capital, Labcorp Venture Fund, and Carle Health. A separate $20 million federal contract comes from BARDA. BARDA, the Biomedical Advanced Research and Development Authority, supports public health preparedness. This combined capital empowers significant expansion. It targets precision critical care development.
The Series A funding primarily fuels commercialization. Prenosis leads with Sepsis ImmunoScore. This is the first FDA-authorized AI diagnostic for sepsis. Sepsis kills more people annually than all cancers combined. It often goes undetected early. Current broad-spectrum treatments lack precision. ImmunoScore integrates biological markers. It combines them with clinical data. This AI tool predicts sepsis risk faster. Human observation alone cannot match its speed. Early detection is crucial for sepsis. The first hours are often called the "golden hour." Catching sepsis then prevents irreversible organ damage. This funding will deploy the tool widely. Hospitals will integrate it into their workflows. It aims to save more lives. It empowers timely clinical interventions.
The BARDA contract focuses on treatment innovation. It falls under the "Type to Treat Program." This $20 million federal investment funds a groundbreaking study. The cornerstone is a large randomized controlled trial. It will enroll 800 patients. All participants suffer from severe respiratory infections. The goal is clear. The trial validates an AI companion diagnostic. This AI tool guides corticosteroid use.
Corticosteroids are common in critical care. Their use remains controversial. They benefit some patients. They harm others. Doctors currently lack precise guidance. Prenosis's AI offers a solution. It identifies specific biological profiles. These profiles indicate which patients will benefit. This technology eliminates guesswork. It promises more targeted therapies. This moves critical care away from generic "one-size-fits-all" protocols. It moves towards personalized treatment plans. This could drastically improve outcomes for conditions like pneumonia and ARDS.
Prenosis's ambition extends beyond diagnostics and specific treatments. The company plans a vast infrastructure initiative. It will integrate its Immunix™ platform. This proprietary biology-based technology utilizes deep data. Up to 40 top academic medical centers across the U.S. will join. This creates a "precision medicine clinical trial network." This network is powerful. It rapidly identifies patients. These patients possess specific biological traits. Such identification is vital for therapeutic clinical trials. It accelerates drug development. It makes trials more efficient. New therapies reach patients faster. This platform drives future AI-based diagnostic advancements.
Current critical care often employs a "one-size-fits-all" approach. This model struggles with complex conditions. Sepsis is a prime example. Pneumonia and ARDS also present challenges. These conditions vary greatly among individuals. Patient immune systems react differently. Prenosis's technology addresses this variability directly. Its deep data and AI capabilities unlock patient-specific insights.
The Immunix platform forms the backbone. It analyzes unique biological profiles. This allows for truly personalized care. Doctors can make more informed decisions. They can tailor interventions. This strategy optimizes patient outcomes. It minimizes adverse effects. This marks a paradigm shift in critical care delivery. It moves medicine into a new era of biological understanding.
Prenosis stands at the forefront of healthcare technology. Its advancements merge biology and artificial intelligence. This creates powerful diagnostic and therapeutic tools. The company's work impacts a wide range of critical conditions. It provides a blueprint for future medical innovation. The FDA authorization of Sepsis ImmunoScore sets a precedent. It validates AI's role in diagnostics. This milestone paves the way for further AI integration in medicine.
The BARDA funding highlights government recognition. It underscores the potential of AI-driven precision medicine. Public and private investments converge. They accelerate medical progress. This collective effort improves patient care standards. It offers hope for diseases previously resistant to personalized approaches. It strengthens national health security.
The future of critical care looks smarter. It looks more precise. Prenosis paves this path. Its technology offers granular understanding. It deciphers individual immune responses. This leads to better treatments. It saves more lives. The company's network builds a foundation. It supports continuous discovery. It facilitates rapid innovation. This is the dawn of a new era. Critical care becomes truly personalized. It delivers targeted interventions based on unique patient biology.
Chicago-based Prenosis announced a major financial milestone. The company secured $40 million in new capital. This funding splits evenly. A $20 million Series A round provides private investment. Premier co-investors include PACE Healthcare Capital, Labcorp Venture Fund, and Carle Health. A separate $20 million federal contract comes from BARDA. BARDA, the Biomedical Advanced Research and Development Authority, supports public health preparedness. This combined capital empowers significant expansion. It targets precision critical care development.
The Series A funding primarily fuels commercialization. Prenosis leads with Sepsis ImmunoScore. This is the first FDA-authorized AI diagnostic for sepsis. Sepsis kills more people annually than all cancers combined. It often goes undetected early. Current broad-spectrum treatments lack precision. ImmunoScore integrates biological markers. It combines them with clinical data. This AI tool predicts sepsis risk faster. Human observation alone cannot match its speed. Early detection is crucial for sepsis. The first hours are often called the "golden hour." Catching sepsis then prevents irreversible organ damage. This funding will deploy the tool widely. Hospitals will integrate it into their workflows. It aims to save more lives. It empowers timely clinical interventions.
The BARDA contract focuses on treatment innovation. It falls under the "Type to Treat Program." This $20 million federal investment funds a groundbreaking study. The cornerstone is a large randomized controlled trial. It will enroll 800 patients. All participants suffer from severe respiratory infections. The goal is clear. The trial validates an AI companion diagnostic. This AI tool guides corticosteroid use.
Corticosteroids are common in critical care. Their use remains controversial. They benefit some patients. They harm others. Doctors currently lack precise guidance. Prenosis's AI offers a solution. It identifies specific biological profiles. These profiles indicate which patients will benefit. This technology eliminates guesswork. It promises more targeted therapies. This moves critical care away from generic "one-size-fits-all" protocols. It moves towards personalized treatment plans. This could drastically improve outcomes for conditions like pneumonia and ARDS.
Prenosis's ambition extends beyond diagnostics and specific treatments. The company plans a vast infrastructure initiative. It will integrate its Immunix™ platform. This proprietary biology-based technology utilizes deep data. Up to 40 top academic medical centers across the U.S. will join. This creates a "precision medicine clinical trial network." This network is powerful. It rapidly identifies patients. These patients possess specific biological traits. Such identification is vital for therapeutic clinical trials. It accelerates drug development. It makes trials more efficient. New therapies reach patients faster. This platform drives future AI-based diagnostic advancements.
Current critical care often employs a "one-size-fits-all" approach. This model struggles with complex conditions. Sepsis is a prime example. Pneumonia and ARDS also present challenges. These conditions vary greatly among individuals. Patient immune systems react differently. Prenosis's technology addresses this variability directly. Its deep data and AI capabilities unlock patient-specific insights.
The Immunix platform forms the backbone. It analyzes unique biological profiles. This allows for truly personalized care. Doctors can make more informed decisions. They can tailor interventions. This strategy optimizes patient outcomes. It minimizes adverse effects. This marks a paradigm shift in critical care delivery. It moves medicine into a new era of biological understanding.
Prenosis stands at the forefront of healthcare technology. Its advancements merge biology and artificial intelligence. This creates powerful diagnostic and therapeutic tools. The company's work impacts a wide range of critical conditions. It provides a blueprint for future medical innovation. The FDA authorization of Sepsis ImmunoScore sets a precedent. It validates AI's role in diagnostics. This milestone paves the way for further AI integration in medicine.
The BARDA funding highlights government recognition. It underscores the potential of AI-driven precision medicine. Public and private investments converge. They accelerate medical progress. This collective effort improves patient care standards. It offers hope for diseases previously resistant to personalized approaches. It strengthens national health security.
The future of critical care looks smarter. It looks more precise. Prenosis paves this path. Its technology offers granular understanding. It deciphers individual immune responses. This leads to better treatments. It saves more lives. The company's network builds a foundation. It supports continuous discovery. It facilitates rapid innovation. This is the dawn of a new era. Critical care becomes truly personalized. It delivers targeted interventions based on unique patient biology.